The Latest Cardiac and Vascular News
MONMOUTH JUNCTION, N.J., July 6, 2021 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO) announces the full approval of its Investigational Device Exemption (IDE) application to conduct the pivotal STAR-T (Safe and Timely Antithrombotic Removal – Ticagrelor) double-blind, randomized, controlled trial (RCT) in the United States to support FDA regulatory clearance. This study is being performed under the previously announced FDA Breakthrough […]
– The EMPEROR-Preserved phase III trial met its primary endpoint and demonstrated significant risk reduction with Jardiance for the composite of cardiovascular death or hospitalization for heart failure in adults with heart failure with preserved ejection fraction – Heart failure with preserved ejection fraction has been classified as “the single […]
Ghent, BELGIUM – 6 July 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that the positive results from its RED DESERT study of alfapump DSR® (Direct Sodium Removal) which were presented at the Heart Failure […]
• Multicenter, double-blinded, controlled study designed to evaluate safety & efficacy of Lomecel-B intramyocardial injection in infants with HLHS • Funded by the National Heart, Lung and Blood Institute (Grant number 1UG3HL148318 and 1U24HL148316) in collaboration with Longeveron MIAMI, July 06, 2021 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or […]
PARIS, July 05, 2021 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), biopharmaceutical company specializing in the development of a new class of drugs acting directly on the brain to treat resistant high blood pressure and heart failure, will present results of a preclinical study of QGC606 in heart failure […]
July 01, 2021 FDA 510k-cleared real-time 3D intracardiac echocardiography (ICE) catheter has potential to improve standard of care for structural heart disease and electrophysiology procedures Reduced need for general anesthesia accelerates workflows, increases efficiency, and broadens treatment options Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in […]
The RESTORE trial will test the safety and efficacy of the HARPOON™ Beating Heart Mitral Valve Repair System. New minimally invasive device could reduce pain, complications and recovery time for mitral valve repair surgery. Hoag is one of only 40 sites in the world selected for this trial. NEWPORT BEACH, […]
REGULATED INFORMATION – INSIDE INFORMATION 1 July 2021, 07:00 am CEST Interim data from 26 patients in the Roll-In Cohort reconfirm positive outcomes against all primary endpointsi Over 90% reduction in mean frequency of therapeutic paracentesis versus baseline All patients experienced at least 50% reduction in mean frequency of therapeutic paracentesis per month versus baseline Clinically important improvement in quality of life maintained even up to 12 months post-implantation Safety profile remains in line […]
Merck and NGM will continue their research, discovery and development collaboration with a narrower scope, focused primarily on retinal and cardiovascular and metabolic (CVM) targets of interest to Merck Merck will continue to advance MK-3655, an FGFR1c/KLB agonistic antibody, currently in an ongoing global Phase 2b clinical trial in patients […]
Atlas, Carta’s AI-assisted data abstraction software, seamlessly automates submission to the ACC’s CathPCI clinical data registry, allowing healthcare organizations to maximize the benefits of registry contributions SAN FRANCISCO–(BUSINESS WIRE)–Carta Healthcare, a provider of artificial intelligence (AI)-powered clinical data abstraction technology and services, today announced that it is now a certified […]
